The Netherlands-based QIAGEN has introduced its EZ2 Connect MDx platform for wide-scale use in automated sample processing in diagnostic laboratories.
The EZ2 Connect MDx enables labs to parallel purify DNA and RNA from 24 samples with a high level of automation in as little as 30 minutes.
According to the firm, the in-vitro device (IVD) now has the CE-IVD compliance marking for the European Union and other nations that recognise this certification.
QIAGEN Molecular Diagnostics Business Area head Jean-Pascal Viola said: “EZ2 Connect MDx puts standardised and efficient nucleic acid purification in reach of any clinical lab.
“It solves the challenges of many clinical diagnostics labs that have to provide diagnostics results quickly, that have to deal with fluctuating sample numbers as well as a large variety of sample types and quality.”
QIAGEN said that EZ2 Connect MDx can extract nucleic acids from blood plasma, serum, faeces, and other sample types using magnetic-bead technology.
Reagent cartridges that are prefilled and sealed, as well as load checking via embedded cameras, ensure high process safety. Additionally, it includes automated piercing of the sealed cartridge, onboard pipetting and heating, and UV disinfection.
The resulting analyte is compatible with a variety of downstream technologies like real-time PCR, digital PCR and next-generation sequencing.
The company said the latest offering complements the automated IVD nucleic extraction platforms from QIAGEN, including QIAcube Connect MDx and QIAsymphony.
The kit catalogue and adaptable procedures offered by QIAGEN enable EZ2 Connect MDx to handle a variety of sample types.
It can be utilised in specialised IVD mode with EZ1 DSP kits and protocols for diagnostic workflows, or in research mode with research kits (MBA), QIAGEN added.
The Dutch firm said that the device has the ability to use the QIAsphere digital laboratory environment, which provides complete integration into a lab’s digital infrastructure and allows for remote instrument management.
